SWOG clinical trial number
S9704

A Randomized Phase III Trial Comparing Early High Dose Chemoradiotherapy and an Autologous Stem Cell Transplant to Conventional Dose CHOP Chemotherapy Plus Rituximab for CD20+ B Cell Lymphomas(with Possible Late Autologous Stem Cell Transplant) for Patients with Diffuse Aggressive Non-Hodgkin's Lymphoma in the High-Intermediate and High Risk International Classification Prognostic Groups (A BMT Study)

Closed
Phase
Accrual
100%
Published
Abbreviated Title
NON-HODGKIN'S: CHOP x 8 vs. CHOP x 6 followed by TBI/VP-6/cylophosphamide or SWOG BCV with stem cell rescue
Activated
09/15/1997
Closed
12/15/2007
Participants
NCORP, Members, Medical Oncologists, Radiation Oncologists, Pathologists, ECOG, CALGB, NCIC-CTG, Affiliates

Research committees

Lymphoma

Treatment

Cyclophosphamide Prednisone Vincristine BCNU Doxorubicin Rituximab VP-16 Radiation Therapy CHOP RT

Eligibility Criteria Expand/Collapse

Biopsy proven intermediate or high grade non-Hodgkin's lymphoma (Working formulation groups D through H and J) except lymphoblastic lymphoma (Working formulation group I); no transformed lymphomas; High-Intermediate or High Risk Groups; Stage III, Stage IV, or "bulky" Stage II; bidimensionally measureable disease; BM aspirate and biopsy; CT scan of chest, abdomen, and pelvis; no CNS involvement; no non-lymphoma related hepatic and/or renal dysfunction; no prior chemo for lymphoma except for one cycle of CHOP prior to registration (if so all eligibility requirements for first registration must have been completed prior to the start of the first cycle of CHOP); no prior RT for lymphoma; no coronary artery disease, cardiomyopathy, congestive heart failure, or dysrhythmia requiring therapy; no known allergy to etoposide or a history of Grade 3 hemorrhagic cystitis with cyclophosphamide; no known AIDS or HIV.

Publication Information Expand/Collapse

2019

Autologous Transplantation as Consolidation for High Risk Aggressive T-Cell Non-Hodgkin's Lymphoma: A SWOG 9704 Intergroup Trial Subgroup Analysis

Z Al-Mansour;H Li;JR Cook;LS Constine;S Couban;DA Stewart;TC Shea;P Porcu;JN Winter;BS Kahl;S Smith;DC Marcellus;KP Barton;GM Mills;M LeBlanc;L Rimsza;SJ Forman;JP Leonard;RI Fisher;JW Friedberg;PJ Stiff Leukemia and Lymphoma Aug;60(8):1934-1941; Jan 10:1-8. doi: 10.1080/10428194.2018.1563691. [Epub ahead of print]

PMid: PMID30628511 | PMC number: PMC6620162

2018

Survival by Hispanic Ethnicity among Cancer Patients Participating in SWOG Clinical Trials

M Chavez-MacGregor;J Unger;A Moseley;S Ramsey;DL Hershman Cancer Apr 15;124(8):1760-1769; Jan 25 [Epub ahead of print]

PMid: PMID29370458 | PMC number: PMC5963502

2016

Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: Subset analysis of randomized trial intergroup S9704

SD Puvvada;P Stiff;M Leblanc;JR Cook;S Couban;JP Leonard;B Kahl;D Marcellus;T Shea;JN Winter;H Li;LM Rimsza;JW Friedberg;S Smith British Journal of Haematology Sep;174(5):686-691; 2016 Apr 13 [Epub ahead of print]

PMid: PMID27072903 | PMC number: PMC5125530

Beyond RCHOP: A blueprint for diffuse large B-cell lymphoma research

GS Nowakowski;KA Blum;JW Friedberg;L Baizer;R Little;D Maloney;LH Sehn;ME Williams;W Wilson;JP Leonard;SM Smith Journal of the National Cancer Institute Dec 16;108(12). pii: djw257. Print 2016 Dec.

PMid: PMID27986884 | PMC number: pending

Autologous transplantation as consolidation for high risk aggressive t-cell non-Hodgkin’s lymphoma: a SWOG S9704 intergroup trial subgroup analysis

PJ Stiff;H Li;JR Cook;LS Constine;S Couban;DA Stewart;TC Shea;P Porcu;JN Winter;BS Kahl;SM Smith;D Marcellus;KP Barton;GM Mills;M LeBlanc;LM Rimsza;SJ Forman;JP Leonard;RI Fisher;JW Friedberg Blood 128:4651; American Society of Hematology Annual Meeting (December 3-6, 2016, San Hematology Annual Meeting (December 3-6, 2016, SanDiego, CA), poster

2014

Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma

H Gustafson (Tardif);S Yao;B Goldman;K Lee;C Spier;M LeBlanc;L Rimsza;JR Cernan;TM Habermann;BK Link;MJ Mauer;SL Slager;D Persky;T Miller;RI Fisher;C Ambrosone;M Briehl American Journal of Hematology 89(6):639-645;

PMid: PMID24633940 | PMC number: PMC4137041

Clinical significance of MYC protein expression and/or high grade morphology in non-Burkitt, diffuse aggressive B-cell non-Hodgkin lymphomas: a SWOG S9704 correlative study

JR Cook;B Goldman;RR Tubbs;L Rimsza;M LeBlanc;P Stiff;RI Fisher American Journal of Surgical Pathology 38(4):494-501;

PMid: PMID24625415 | PMC number: PMC3955880

The role of myeloablation for lymphoma

PJ Stiff;JM Unger;RI Fisher New England Journal of Medicine 370(6):575-576

PMid: PMID24499218 | PMC number: n/a - correspondence not within the scope of Public Access Policy

Double hit lymphoma and double positive lymphoma: subset analyses of MYC positive patients of SWOG S9704

S Puvvada;P Stiff;M Leblanc;JR Cook;BS Kahl;H Li;L Rimsza;JW Friedberg;SM Smith Blood 124(21):1710; American Society for Hematology (December 6-9, 2014, San Francisco, CA), poster;

2013

Autologous transplant as consolidation for aggressive non-hodgkin's lymphoma

P Stiff;J Unger;J Cook;L Constine;S Couban;D Stewart;T Shea;P Porcu;J Winter;BS Kahl;T Miller;R Tubbs;D Marcellus;J Friedberg;K Barton;G Mills;M Leblanc;L Rimsza;S Forman;RI Fisher New England Journal of Medicine, 369(18):1681-1690;

PMid: PMID24171516 | PMC number: PMC3985418

2012

MYC protein expression, but not high grade morphology, is associated with poor outcome in non-Burkitt diffuse aggressive B-cell lymphomas: a SWOG S9704 correlative study

JR Cook;B Goldman;RR Tubbs;L Rimsza;M LeBlanc;P Stiff;RI Fisher Blood 120(21):abst.543; American Society of Hematology Annual Meeting, oral;

2011

Randomized phase III US/Canadian intergroup trial (SWOG S9704) comparing CHOP+/- R x 8 vs. CHOP +/- R x 6 followed by high dose therapy and autotransplant for patients with diffuse aggressive non-Hodgkin's lymphoma (NHL) in the high-intermediate (H-Int) or high IPI risk groups

P Stiff;J Unger;J Cook;L Constine;S Couban;T Shea;JN Winter;TP Miller;RR Tubbs;D Marcellus;J Friedberg;K Barton;G Mills;M LeBlanc;L Rimsza;S Forman;RI Fisher Journal of Clinical Oncology 29:(suppl; abstr 8001); ASCO 2011 Annual Meeting, oral presentation

2010

Diffuse large B-cell lymphomas with high grade morphologic features and/or MYC translocations lack distinctive clinicopathologic features at presentation: a SWOG S9704 study

J Cook;R Tubbs;L Rimsza;P Stiff;M LeBlanc;R Fisher;B Goldman United States and Canadian Academy of Pathology 99th Annual Meeting, abst #1308 (3/20-26, 2010, Wash DC); poster

Other Clinical Trials

SWOG Clinical Trial Number
S2207

Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma
Research Committee(s)
Lymphoma
Activated
06/30/2023
Accrual
5%
Open
Phase
SWOG Clinical Trial Number
CTSU/AHOD2131

A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Research Committee(s)
Lymphoma
Immunomolecular Therapeutics
Activated
04/28/2023
Open
Phase
SWOG Clinical Trial Number
S2114

A Randomized Phase II trial of consolidation therapy following CD19 CAR T-cell treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
02/23/2023
Accrual
10%
Open
Phase